Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INBRX-106 +/- Pembrolizumab in Advanced Solid Tumors
NCT04198766Phase 2Recruiting
- Sponsor
- Inhibrx Biosciences
- Start
- Dec 2019
- Primary completion
- Jul 2033
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of inbrx-106 in solid tumor, non-small cell lung cancer (NSCLC), head and neck cancer (HNC), melanoma, gastric cancer (GC), sponsored by Inhibrx Biosciences. Started Dec 2019; status: recruiting.
02
Drugs
inbrx-106
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)head and neck cancer (HNC)melanomagastric cancer (GC)
Beyond the preview
Go deeper on NCT04198766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04198766.